Molecular diagnostics in the treatment of leukemia

Current Opinion in Hematology

Volumn 6, Issue 4, 1999, Pages 229-235

  Rubnitz, Jeffrey E ^a   Pui, Ching Hon ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ARSENIC TRIOXIDE; CELL DNA; CYTARABINE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHILDHOOD CANCER; DNA DETERMINATION; DRUG EFFICACY; GENE FUSION; GENETIC ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

HUMANS; LEUKEMIA; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; TRANSLOCATION, GENETIC;

EID: 0032800740     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199907000-00006     Document Type: Review

References (73)

1. Rubnitz JE, Pui C-H, Downing JR: The role of TEL fusion genes in pediatric leukemias. Leukemia 1999, 13:6-13.
2. Borkhardt A, Harbott J, Lampert F: Biology and clinical significance of the TEL/AML1 rearrangement. Curr Opin Pediatr 1999, 11:33-38.
3. Pui C-H, Rubnitz JE, Hancock ML, Downing JR, Raimondi SC, Rivera GK, et al.: Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol 1998, 16:3768-3773.
4. Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, Camitta B: Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. Leukemia 1998, 12:1764-1770.
5. Loncarevic IF, Roitzheim B, Ritterbach J, Viehmann S, Borkhardt A, Lampert F, Harbott J: Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion. Genes Chromosomes Cancer 1999, 24:272-277.
6. Takahashi Y, Horibe K, Kiyoi H, Miyashita Y, Fukuda M, Mori H, et al.: Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998, 20:190-195.
7. Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C, et al., for the Berlin-Frankfurt-Munster Study Group: TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. Blood 1998, 91:1716-1722.
8. Loh ML, Silverman LB, Young ML, Neuberg D, Golub TR, Sallan SE, Gilliland DG: Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood 1998, 92:4792-4797.
9. Rubnitz JE, Behm FG, Wichlan D, Ryan C, Sandlund JT, Ribeiro RC, et al.: Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup. Leukemia 1999, 13:19-21.
10. Zuna J, Hrusak O, Kalinova M, Muzikova K, Stary J, Trka J: TEL/AML1 positivity in childhood ALL: average or better prognosis? Leukemia 1999, 13:22-24.
11. Pui C-H, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 1998, 339:605-614. This review summarizes recent advances in both the characterization of leukemic cells and the treatment of ALL.
12. Faderl S, Kantarjian HM, Talpaz M, Estrov Z: Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998, 91:3995-4019.
13. Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ, et al.: Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1998, 16:527-535.
14. Hunger SP, Fall MZ, Camitta BM, Carroll AJ, Link MP, Lauer SJ, et al.: E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1998, 91: 1021-1028.
15. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, et al.: Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer 1998, 83:2030-2039.
16. Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V, et al.: Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998, 92:2730-2741. Initial response to prednisone was an important predictor of outcome among 61 children with BCR-ABL-positive ALL. The four-year EFS estimate for patients with a PGR was 55% (± 8%); that for patients with a PPR was 10% (± 7%).
17. Marks DI, Bird JM, Cornish JM, Goulden NJ, Jones CG, Knechtli CJ, et al.: Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia. J Clin Oncol 1998, 16:931-936.
18. Johansson B, Moorman AV, Haas OA, Watmore AE, Cheung KL, Swanton S, Secker-Walker LM: Hematologic malignancies with t(4;11)(q21;q23)-a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. Leukemia 1998, 12:779-787. The finding of a favorable prognosis of children two to nine years of age with the t(4;11) confirms the results of our previous study (Pui et al., Blood 1991, 77:440-447), and supports our notion that that the indication of allogeneic HSCT should not be based solely on genetic abnormalities.
19. Moorman AV, Hagemeijer A, Charrin C, Rieder H, Secker-Walker LM: The translocations, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 patients. Leukemia 1998, 12:805-810.
20. Lillington DM, Young BD, Berger R, Martineau M, Moorman AV, Secker-Walker LM, and the European 11q23 Workshop participants: The t(10;11)(p12;q23) translocation in acute leukaemia: a cytogenetic and clinical study of 20 patients. Leukemia 1998, 12:801-804.
21. Swansbury GJ, Slater R, Bain BJ, Moorman AV, Secker-Walker LM, and the European 11q23 Workshop participants: Hematological malignancies with t(9;11)(p21-22;q23)-a laboratory and clinical study of 125 cases. Leukemia 1998, 12:792-800.
22. Martineau M, Berger R, Lillington DM, Moorman AV, Secker-Walker LM, and the European Concerted Action 11q23 Workshop participants: The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. Leukemia 1998, 12:788-791.
23. Hunger SP, McGavran L, Meltesen L, Parker NB, Kassenbrock CK, Bitter MA: Oncogenesis in utero: fetal death due to acute myelogenous leukaemia with an MLL translocation. Br J Haematol 1998, 103:539-542.
24. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, et al.: Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998, 92:1898-1909. The addition of high-dose cytarabine and mitoxantrone to standard therapy eliminated the prognostic impact of the t(4;11) among adult patients with pro-B ALL. In this study, the probability of CCR for patients with t(4;11)/MLL-AF4 did not differ significantly with the probability of remission for those patients without this genetic abnormality.
25. Rubnitz JE, Camitta BM, Mahmoud H, Raimondi SC, Carroll AJ, Borowitz MJ, et al.: Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. J Clin Oncol 1999, 17:191-196. The MLL-ENL fusion was associated with a favorable outcome for B-precursor patients one to 10 years of age and for T-cell patients. No relapses occurred in these patient subgroups.
26. Pui C-H, Evans WE: Acute lymphoblastic leukemia in infants. J Clin Oncol 1999, 17:438-440.
27. Cave H, van der Werff ten Bosch, Suciu S, Guidal C, Waterkeyn C, Otten J, et al., for the European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998, 339:591-598. In this study of 178 children with ALL, the presence and level of MRD at four time points were predictive of survival. A multivariate analysis that included immunophenotype, age, and leukocyte count at the time of diagnosis showed that residual disease was the most important prognostic factor.
28. -3 at both time points and had a relapse rate of 75% (95% CI, 55% to 95%); and the remaining patients (intermediate-risk) had a relapse rate of 23% (95% CI, 13% to 36%).
29. Evans PA, Short MA, Owen RG, Jack AS, Forsyth PD, Shiach CR, et al.: Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia. J Clin Oncol 1998, 16:3616-3627.
30. Gruhn B, Hongeng S, Yi H, Hancock ML, Rubnitz JE, Neale GA, Kitchingman GR: Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998, 12:675-681.
31. Goglden NJ, Knechtli CJ, Garland RJ, Langlands K, Hancock JP, Potter MN, et al.: Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 1998, 100:235-244.
32. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, et al.: Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998, 92:4072-4079.
33. Knechtli CJ, Goulden NJ, Hancock JP, Harris EL, Garland RJ, Jones CG, et al.: Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998, 102:860-871.
34. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998, 92:3362-3367.
35. Uckun FM, Herman-Hatten K, Crotty ML, Sensel MG, Sather HN, Tuel-Ahlgren L, et al.: Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood 1998, 92:810-821.
36. Hunger SP, Cleary ML: What significance should we attribute to the detection of MLL fusion transcripts? Blood 1998, 92:709-711.
37. Schnittger S, Wormann B, Hiddemann W, Griesinger F: Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood 1998, 92:1728-1734.
38. Trka J, Zuna J, Hrusak O, Michalova K, Kalinova M, Stary J: No evidence for MLL/AF4 expression in normal cord blood samples. Blood 1999, 93: 1106-1107.
39. Kim-Rouille M-H, MacGregor A, Wiedemann LM, Greaves MF, Navarrete C: MLL-AF4 gene fusions in normal newborns. Blood 1999, 93:1107-1108.
40. Neale GAM, Coustan-Smith E, Pan Q, Chen X, Gruhn B, Stow P, et al.: Detection of minimal residual disease in childhood acute lymphoblastic leukemia with immunologic and molecular methods: a comparative study. Blood 1998, 92(suppl 1):394.
41. Relling MV, Hancock ML, Boyett JM, Pui C-H, Evans WE: Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999, 93:2817-2823.
42. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Kun LE, et al.: High incidence of secondary brain tumors in children with acute lymphoblastic leukemia (ALL) related to antimetabolite therapy. Blood 1998, 92(suppl 1):607.
43. Krynetski EY, Evans WE: Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 1998, 63:11-16.
44. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al., for the Medical Research Council Adult and Children's Leukaemia Working Parties: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998, 92:2322-2333. The MRC identified prognostic subgroups of AML on the basis of karyotype. The t(8;21), t(15;17), and inv(16) karyotypes each predicted a favorable outcome, whereas complex karyotypes (-5, -7, del(5q), or abnormalities of 3q) conferred a poor outcome. These genetic features have subsequently been used to determine the treatment approaches used in the MRC AML 12 trial.
45. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, et al.: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998, 58:4173-4179. In a multivariate analysis, the most important predictors of outcome among de novo AML cases were the use of high-dose cytarabine and the presence of CBF leukemia, ie, AML cases that contained the t(8;21), inv(16), t(16;16), or del(16). The CBF group had the best outcome overall and also demonstrated the greatest benefit from high-dose cytarabine.
46. Viswanatha DS, Chen I, Liu PP, Slovak ML, Rankin C, Head DR, Willman CL: Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias. Blood 1998, 91:1882-1890.
47. Roulston D, Espinosa R III, Nucifora G, Larson RA, Le Beau MM, Rowley JD: CBFA2 (AML1] translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood 1998, 92:2879-2885.
48. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al.: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021-1028.
49. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, et al.: Early detection of relapse by prospective reverse transcriptase- polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial: GIMEMA-AIEOP multicenter "AIDA" trial. Blood 1998, 92:784-789.
50. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP: Pml is essential for multiple apoptotic pathways. Nat Genet 1998, 20:266-272.
51. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H: PML induces a novel caspase-independent death process. Nat Genet 1998, 20:259-265.
52. Collins SJ: Acute promyelocytic leukemia: relieving repression induces remission. Blood 1998, 91:2631-2633.
53. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A: Reduced retinoic acid-sensitivities of nuclear receptor compressor binding to PML- and PLZF-RARa underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998, 91:2634-2642.
54. 3. In addition, eight of these patients no longer had polymerase chain reaction-detectable levels of the PML-RARα fusion transcript.
55. Huang S-Y, Chang C-S, Tang J-L, Tien H-F, Kuo T-L, Huang S-F, et al.: Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998, 103:1092-1095.
56. Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P, Riishj DC, Jorgensen P: Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998, 92:574-588.
57. Scurto P, Rocha MH, Kane JR, Williams WK, Haney DM, Conn WP, et al.: A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia. Leukemia 1998, 12:1994-2005.
58. Haas O, Henn T, Romanakis K, du Manoir S, Lengauer C: Comparative genomic hybridization as part of a new diagnostic strategy in childhood hyperdiploid acute lymphoblastic leukemia. Leukemia 1998, 12:474-481.
59. Larramendy ML, Huhta T, Vettenranta K, el-Rifai W, Lundin J, Pakkala S, et al.: Comparative genomic hybridization in childhood acute lymphoblastic leukemia. Leukemia 1998, 12:1638-1644.
60. Chambon-Pautas C, Cave H, Gerard B, Guidal-Giroux C, Duval M, Vilmer E, Grandchamp B: High-resolution allelotype analysis of childhood B-lineage acute lymphoblastic leukemia. Leukemia 1998, 12:1107-1113.
61. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, et al.: Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998, 280:1077-1082.
62. Chu S, DeRisi J, Eisen M, Mulholland J, Botstein D, Brown PO, Herskowitz I: The transcriptional program of sporulation in budding yeast. Science 1998, 282:699-705.
63. Cho RJ, Campbell MJ, Winzeler EA, Steinmetz L, Conway A, Wodicka L, et al.: A genome-wide transcriptional analysis of the mitotic cell cycle. Mol Cell 1998, 2:65-73.
64. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al.: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847.
65. Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, et al.: Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 1998, 4:1293-1301.
66. Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, et al.: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281:533-538.
67. Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, et al.: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998, 91:458-465.
68. Patel V, Senderowicz AM, Pinto D, Igishi T, Raffeld M, Quintanilla-Martinez L, et al.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998, 102:1674-1681.
69. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, et al.: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998, 16:2986-2999.
70. Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, et al.: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998, 91:2482-2490.
71. Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, et al.: Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother Pharmacol 1998, 42(suppl):54-59.
72. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, et al.: Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 1998, 58:3248-3253.
73. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, et al.: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998, 4:1661-1672.